MyoKardia, Inc. today announced that data from the company’s Phase 2a multiple-ascending dose study of danicamtiv (formerly MYK-491) in patients with chronic heart failure with reduced ejection fraction (HFrEF) will be presented in a late-breaker session at the European Society of Cardiology’s Virtual Heart Failure Association Discoveries (HFA Discoveries) event. Danicamtiv is MyoKardia’s lead activator candidate designed to increase the contractility of the heart (systolic function) with minimal or no effect on myocardial relaxation and compliance (diastolic function) by acting directly on the proteins in the heart muscle responsible for contraction.
Friday, June 19, 2020
Late-Breaking Science Session 6 – Pharmacotherapy
5:00 p.m. – 5:45 p.m. CEST (11:00 a.m. – 11:45 a.m. ET)
Oral Presentation: Phase 2a Study of Danicamtiv (MYK-491) in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF)
Presented by Adriaan Voors, M.D., Ph.D., University Medical Center Groningen, Groningen, Netherlands
HFA Discoveries will also publish data from nonclinical studies elucidating danicamtiv’s mechanism of activity in a presentation titled, “Danicamtiv (MYK-491) A Novel Small-Molecule Cardiac Activator: in vitro/in vivo Evidence for Overall Myocardial Inotropy,” by Carlos del Rio, PhD, FACC, MyoKardia Staff Scientist, Pharmacology.